OSONENCT03976180
High-flow Oxygen for Vaso-occlusive Pain Crisis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary and study completion dates pushed to Nov 27, 2025
- Eligibility criteria expanded, about 32 words
Notable Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
- Primary completion date: May 14, 2021 to Nov 10, 2021
- Study sites: 0 to 1
- Study completion date: May 29, 2021 to Nov 27, 2021
- Start date changed from estimate of Feb 1, 2020 to Apr 27, 2020
- Notable Start date: Dec 1, 2019 to Feb 1, 2020
- Primary completion date: Mar 14, 2021 to May 14, 2021
- Study completion date: Mar 29, 2021 to May 29, 2021
- Notable Start date: Sep 1, 2019 to Dec 1, 2019v3
- Notable Start date: Jun 1, 2019 to Sep 1, 2019
- Primary completion date: Dec 14, 2020 to Mar 14, 2021
- Study completion date: Dec 29, 2020 to Mar 29, 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
Devices: Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%), HFNO with high FiO2 (100%)
Sites
1 site in 1 country
- Henri MondorCréteil, France